RWA
ALNY icon

Ropes Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ropes Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-75
Closed -$5K – 485
2016
Q3 		$5K Hold
75
– – ﹤0.01% 430
2016
Q2 		$4K Buy
+75
New +$4.72K ﹤0.01% 402

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ropes Wealth Advisors's ALNY Position: Q4 2016 in Review

Ropes Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 75 shares — an estimated $5K sold.

Ropes Wealth Advisors first reported a position in ALNY in Q2 2016 and held it in 2 quarters. The position peaked at $5K in Q3 2016. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

  • Ropes Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Ropes Wealth Advisors sold 75 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $5K.
  • Ropes Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Ropes Wealth Advisors's Alnylam Pharmaceuticals position peaked at $5K in Q3 2016.
  • 211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Ropes Wealth Advisors's 13F filing for Q4 2016, filed 6 Jan 2017.